NAYA Biosciences Common Stock Statistics Share Statistics NAYA Biosciences Common Stock has 928.27K
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 928.27K Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) n/a Shares Floating n/a Failed to Deliver (FTD) Shares 620 FTD / Avg. Volume 0.04%
Short Selling Information The latest short interest is 95.08K, so 10.24% of the outstanding
shares have been sold short.
Short Interest 95.08K Short % of Shares Out 10.24% Short % of Float 10.27% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.18 and the forward
PE ratio is -0.6.
NAYA Biosciences Common Stock's PEG ratio is
0.
PE Ratio -0.18 Forward PE -0.6 PS Ratio 0.26 Forward PS 0.2 PB Ratio 0.13 P/FCF Ratio -0.53 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for NAYA Biosciences Common Stock.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.07,
with a Debt / Equity ratio of 0.78.
Current Ratio 0.07 Quick Ratio 0.06 Debt / Equity 0.78 Debt / EBITDA -1.39 Debt / FCF -3.13 Interest Coverage -7.69
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $197.94K Profits Per Employee $-275.63K Employee Count 33 Asset Turnover 0.14 Inventory Turnover 16.64
Taxes Income Tax -22.91K Effective Tax Rate 0.25%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0, so NAYA Biosciences Common Stock's
price volatility has been lower than the market average.
Beta 0 52-Week Price Change n/a 50-Day Moving Average 3.03 200-Day Moving Average n/a Relative Strength Index (RSI) 35.58 Average Volume (20 Days) 1,401,365
Income Statement In the last 12 months, NAYA Biosciences Common Stock had revenue of 6.53M
and earned -9.1M
in profits. Earnings per share was -30.19.
Revenue 6.53M Gross Profit 2.87M Operating Income -8.13M Net Income -9.1M EBITDA -7.14M EBIT -8.06M Earnings Per Share (EPS) -30.19
Full Income Statement Balance Sheet The company has 741.4K in cash and 9.9M in
debt, giving a net cash position of -9.15M.
Cash & Cash Equivalents 741.4K Total Debt 9.9M Net Cash -9.15M Retained Earnings -67.16M Total Assets 31.74M Working Capital -17.15M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.97M
and capital expenditures -183.7K, giving a free cash flow of -3.16M.
Operating Cash Flow -2.97M Capital Expenditures -183.7K Free Cash Flow -3.16M FCF Per Share -10.2
Full Cash Flow Statement Margins Gross margin is 44%, with operating and profit margins of -124.4% and -139.25%.
Gross Margin 44% Operating Margin -124.4% Pretax Margin -139.6% Profit Margin -139.25% EBITDA Margin -109.35% EBIT Margin -124.4% FCF Margin -48.35%
Dividends & Yields IVF does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for IVF.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 21, 2025. It was a
backward
split with a ratio of 1:3.
Last Split Date Jul 21, 2025 Split Type backward Split Ratio 1:3
Scores Altman Z-Score -6.62 Piotroski F-Score 3
